12-Month follow-up study of drug treatment in pathological gamblers: A primary outcome study

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 620-624

  Dannon, Pinhas N ^a,b,c   Lowengrub, Katherine ^a,b   Musin, Ernest ^b   Gonopolsky, Yehudit ^b   Kotler, Moshe ^a,b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Rehovot Community Mental Health and Rehabilitation Clinic   (Israel)

^c Beer Yaakov Mental Health Hospital   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; FLUVOXAMINE; NALTREXONE; TOPIRAMATE; DRUG DERIVATIVE; FRUCTOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG DOSE REDUCTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RELAPSE; SAMPLE SIZE; SELF REPORT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ANALYSIS OF VARIANCE; DELAYED RELEASE FORMULATION; DRUG THERAPY; ISRAEL; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; QUESTIONNAIRE; RECURRENT DISEASE; REPRODUCIBILITY; STATISTICS; TIME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BUPROPION; DELAYED-ACTION PREPARATIONS; DRUG THERAPY; FLUVOXAMINE; FOLLOW-UP STUDIES; FRUCTOSE; GAMBLING; HUMANS; ISRAEL; MALE; MIDDLE AGED; NALTREXONE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; PSYCHOPHARMACOLOGY; QUESTIONNAIRES; RECURRENCE; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 39649102984     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31815a4400     Document Type: Article

References (28)

1. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disorder gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89:1369-1376.
2. Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am. 2000;23:629-642.
3. Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemol Ment Health. 2005;1:21.
4. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry. 2000;47:813-817.
5. Kim SW, Grant J, Adson DE, et al. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
6. Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15.
7. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18:243-249.
8. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921.
9. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16:285-289.
10. Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;25(6):593-596.
11. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol. 2005;28:6-10.
12. Black D. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2004;24:108-109.
13. Dannon PN, Lowengrub K, Musin E, et al. Sustained release bupropion in the treatment of SSRI nonresponder pathological gamblers: pilot study and review of the literature. Therapy. 2005;2:753-759.
14. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
15. Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling. Behav Cognitive Psychother. 1996;24:51-72.
16. Sylvain C, Ladouceur R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol. 1997;65:727-732.
17. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM) 76-338; 1976.
20. Lesieur H, Blume SB. The South Oaks Gambling Screen (the SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry. 1987;144:1184-1188.
21. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155(suppl):1-34.
22. Dell'Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr. 2005;10:619-621.
23. Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. J Gambl Stud. 2003;19:85-109.
24. Kertzman S, Lowengrub K, Aizer A, et al. Stroop performance in pathological gamblers. Psychiatry Res. 2006;142:1-10.
25. Brand M, Kalbe E, Labudda K, et al. Decision-making impairments in patients wtih pathological gambling. Psychiatry Res. 2005;133:91-99.
26. Tavares H, Zilberman ML, el-Guebaly N. Are there cognitive and behavioural approaches specific to the treatment of pathological gambling? Can J Psychiatry. 2003;48:22-27.
27. Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol. 2006;74:555-567.
28. Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two U.S. national surveys. Am J Psychiatry. 2006;163:297-302.